Your browser doesn't support javascript.
loading
Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib.
de Haan, R; van Werkhoven, E; van den Heuvel, M M; Peulen, H M U; Sonke, G S; Elkhuizen, P; van den Brekel, M W M; Tesselaar, M E T; Vens, C; Schellens, J H M; van Triest, B; Verheij, M.
Afiliação
  • de Haan R; Department of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands. ro.d.haan@nki.nl.
  • van Werkhoven E; Department of Biometrics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.
  • van den Heuvel MM; Department of Thoracic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066, CX, The Netherlands.
  • Peulen HMU; Department of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.
  • Sonke GS; Department of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.
  • Elkhuizen P; Department of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.
  • van den Brekel MWM; Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.
  • Tesselaar MET; Department of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.
  • Vens C; Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.
  • Schellens JHM; Division of Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.
  • van Triest B; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
  • Verheij M; Department of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.
BMC Cancer ; 19(1): 901, 2019 Sep 10.
Article em En | MEDLINE | ID: mdl-31500595
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ftalazinas / Piperazinas / Neoplasias / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Holanda País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ftalazinas / Piperazinas / Neoplasias / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Holanda País de publicação: Reino Unido